Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

CV Sciences (CVSI) EBITDA Margin (2016 - 2025)

Historic EBITDA Margin for CV Sciences (CVSI) over the last 13 years, with Q3 2025 value amounting to 8.45%.

  • CV Sciences' EBITDA Margin rose 3800.0% to 8.45% in Q3 2025 from the same period last year, while for Sep 2025 it was 7.25%, marking a year-over-year increase of 83300.0%. This contributed to the annual value of 13.94% for FY2024, which is 349400.0% down from last year.
  • According to the latest figures from Q3 2025, CV Sciences' EBITDA Margin is 8.45%, which was up 3800.0% from 3.62% recorded in Q2 2025.
  • In the past 5 years, CV Sciences' EBITDA Margin registered a high of 138.91% during Q1 2023, and its lowest value of 177.96% during Q4 2021.
  • Over the past 5 years, CV Sciences' median EBITDA Margin value was 23.39% (recorded in 2023), while the average stood at 27.76%.
  • As far as peak fluctuations go, CV Sciences' EBITDA Margin skyrocketed by 1729800bps in 2023, and later crashed by -1544000bps in 2024.
  • Quarter analysis of 5 years shows CV Sciences' EBITDA Margin stood at 177.96% in 2021, then surged by 69bps to 54.92% in 2022, then soared by 57bps to 23.39% in 2023, then increased by 29bps to 16.63% in 2024, then surged by 49bps to 8.45% in 2025.
  • Its EBITDA Margin stands at 8.45% for Q3 2025, versus 3.62% for Q2 2025 and 0.31% for Q1 2025.